Thomas Rowland's most recent trade in ANI Pharmaceuticals Inc was a trade of 4,975 Common Stock done at an average price of $85.7 . Disclosure was reported to the exchange on Aug. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Sale of securities on an exchange or to another person at price $ 85.71 per share. | 12 Aug 2025 | 4,975 | 40,794 (0%) | 0% | 85.7 | 426,407 | Common Stock |
| ANI Pharmaceuticals Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.89 per share. | 28 Feb 2025 | 627 | 45,465 (0%) | 0% | 61.9 | 38,805 | Common Stock |
| ANI Pharmaceuticals Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,834 | 41,452 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,222 | 46,674 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.92 per share. | 12 Feb 2025 | 582 | 46,092 (0%) | 0% | 58.9 | 34,291 | Common Stock |
| ANI Pharmaceuticals Inc | Thomas Rowland | SVP, HEAD - ESTABLISHED BRANDS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.58 per share. | 15 Nov 2024 | 867 | 33,169 (0%) | 0% | 56.6 | 49,055 | Common Stock |